Free tool
Rare disease stocks
We cover 5 companies grouped under the Rare disease theme. The median market value in the group is $10.21B. Across the group, the median move over the past trading day is +0.05%. Price change over the past year runs from −17.1% to +48.5% across the middle 80 percent of the group, with a median of +15.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| ARGX | argenx SE | $1,047.10 | +20.05% | +24.66% | +47.90% | Oct 22, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $65.61 | +5.70% | +10.36% | +11.85% | Oct 26, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% | Sep 21, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% | Oct 26, 2026 |
| INM | InMed Pharmaceuticals Inc. | $1.43 | −14.37% | +27.68% | −36.44% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.